Sindermann H - Search Results

1

Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours.

Vink SR, Schellens JH, Beijnen JH, Sindermann H, Engel J, Dubbelman R, Moppi G, Hillebrand MJ, Bartelink H, Verheij M. Vink SR, et al. Among authors: sindermann h. Radiother Oncol. 2006 Aug;80(2):207-13. doi: 10.1016/j.radonc.2006.07.032. Epub 2006 Aug 17. Radiother Oncol. 2006. PMID: 16914220 Clinical Trial.

2

Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer.

Terwogt JM, Mandjes IA, Sindermann H, Beijnen JH, ten Bokkel Huinink WW. Terwogt JM, et al. Among authors: sindermann h. Br J Cancer. 1999 Mar;79(7-8):1158-61. doi: 10.1038/sj.bjc.6690184. Br J Cancer. 1999. PMID: 10098751 Free PMC article. Clinical Trial.

3

First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumours.

Unger C, Berdel W, Hanauske AR, Sindermann H, Engel J, Mross K. Unger C, et al. Among authors: sindermann h. Eur J Cancer. 2010 Mar;46(5):920-5. doi: 10.1016/j.ejca.2009.12.028. Epub 2010 Jan 14. Eur J Cancer. 2010. PMID: 20079628 Clinical Trial.

4

Development of miltefosine as an oral treatment for leishmaniasis.

Sindermann H, Engel J. Sindermann H, et al. Trans R Soc Trop Med Hyg. 2006 Dec;100 Suppl 1:S17-20. doi: 10.1016/j.trstmh.2006.02.010. Epub 2006 May 26. Trans R Soc Trop Med Hyg. 2006. PMID: 16730362 Review.

5

Miltefosine in visceral leishmaniasis.

Olliaro PL, Ridley RG, Engel J, Sindermann H, Bryceson AD. Olliaro PL, et al. Among authors: sindermann h. Lancet Infect Dis. 2003 Feb;3(2):70. doi: 10.1016/s1473-3099(03)00512-7. Lancet Infect Dis. 2003. PMID: 12560189 No abstract available.

6

Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors.

Emons G, Kaufmann M, Gorchev G, Tsekova V, Gründker C, Günthert AR, Hanker LC, Velikova M, Sindermann H, Engel J, Schally AV. Emons G, et al. Among authors: sindermann h. Gynecol Oncol. 2010 Dec;119(3):457-61. doi: 10.1016/j.ygyno.2010.08.003. Epub 2010 Sep 9. Gynecol Oncol. 2010. PMID: 20828803 Clinical Trial.

7

Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152.

Emons G, Sindermann H, Engel J, Schally AV, Gründker C. Emons G, et al. Among authors: sindermann h. Neuroendocrinology. 2009;90(1):15-8. doi: 10.1159/000225410. Epub 2009 Jun 12. Neuroendocrinology. 2009. PMID: 19521066

8

Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients.

Smorenburg CH, Seynaeve C, Bontenbal M, Planting AS, Sindermann H, Verweij J. Smorenburg CH, et al. Among authors: sindermann h. Anticancer Drugs. 2000 Nov;11(10):825-8. doi: 10.1097/00001813-200011000-00006. Anticancer Drugs. 2000. PMID: 11142690 Clinical Trial.

9

Miltefosine (Impavido): the first oral treatment against leishmaniasis.

Sindermann H, Croft SL, Engel KR, Bommer W, Eibl HJ, Unger C, Engel J. Sindermann H, et al. Med Microbiol Immunol. 2004 Nov;193(4):173-80. doi: 10.1007/s00430-003-0201-2. Epub 2003 Sep 26. Med Microbiol Immunol. 2004. PMID: 14513375

10

Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients.

Unger C, Sindermann H, Peukert M, Hilgard P, Engel J, Eibl H. Unger C, et al. Among authors: sindermann h. Prog Exp Tumor Res. 1992;34:153-9. doi: 10.1159/000420840. Prog Exp Tumor Res. 1992. PMID: 1438798 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

33 results

Search Page

Filters